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switch (OR1.6; 1.2-2.1) and discontinuation (OR1.8; 1.5-2.1). Heart failure was associ-
ated with augmentation (OR1.6; 1.0-2.5) and discontinuation (OR1.7; 1.2-2.4). Age was
inversely associated with augmentation and discontinuation and time since diabetes di-
agnosis was also inversely associated with augmentation. CONCLUSIONS: HbA1c is a
clear driver of treatment regimen changes although there are other factors also
independently related to change such as age, heart failure and baseline OAD.
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OBJECTIVES: In the UK, Oral Anti-Diabetic drugs “OAD” are administered to control
hyperglycaemia in type 2 diabetes when HbA1c exceeds 48mmol/mol. Treatment
guidelines determine initial OAD and subsequent changes in regimen depend on
HbA1c response. Hence, the aim of this study is to quantify OAD treatment
patterns. METHODS: All patients who initiated an OAD (except rosiglitazone) with
first use as index date, in the GPRD database between 1/1/2006 and 25/2/2011 were
included. Periods of continuous and overlapping prescribing (Rx) were used to
define discontinuation, switching and augmentation; a gap of 60 days since expiry
of Rx defined discontinuation. RESULTS: Of 63060 patients commencing OAD, 88%
started on metformin and 8% on gliclazide both as monotherapy. Hence, all other
OAD regimens comprised only 4% of all patients. Compared to metformin, the
gliclazide patient group was older (mean age 67 vs. 61 years) and had higher me-
dian baseline HbA1c (70 (IQR 60-95) vs. 64 (IQR 56-74) mmol/mol). The rate of dis-
continuation of baseline OAD at one year was 32% whilst the discontinuation of all
OAD was 26%. It was rare for discontinuation of OAD to be permanent; only 3.3% of
patients who discontinued in the 1st 12 months did not restart during 4 years. The
rate of switching was 6.4% and the rate of augmentation was 15% over the first year.
These rates differed according to baseline OAD. Compared to metformin the dis-
continuation rate of gliclazide was higher (41% vs. 30%), as was switching (8.4% vs.
6.1%) and augmentation (23% vs. 14%). Lastly, insulin uptake was just 2% by one
year since OAD initiation; again this was higher in the gliclazide group compared to
metformin (7% vs. 1.4%). CONCLUSIONS: Most patients initiated on metformin,
whilst for those initiating on gliclazide, discontinuation, switching, augmentation
and insulin initiation were all higher. Most patients who discontinued OAD subse-
quently restarted.
SYSTEMIC DISORDERS/CONDITIONS - Clinical Outcomes Studies
PSY1
CARDIOVASCULAR AND CONGENITAL SAFETY EVALUATION OF ANTIOBESITY
AGENTS, INCLUDING TOPIRAMATE: A PHARMACOVIGILANCE ANALYSIS OF
THE ADVERSE EVENT REPORTING SYSTEM
Ali AK
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OBJECTIVES: A myriad of pharmacologic agents are developed in attempts to con-
trol obesity, including the extension of the antiepileptic topiramate as an antiobe-
sity agent. However, concerns about the safety of such agents are mounting. This
study aimed at evaluating the cardiovascular and congenital (CC) safety of mar-
keted antiobesity agents, including topiramate. METHODS: A pharmacovigilance
analysis of adverse event reports spontaneously submitted to the US Food and
Drug Administration’s Adverse Event Reporting System (AERS) from 2004 to 2011
was conducted. The Proportional Reporting Ratio (PRR) data mining algorithm is
used to detect signals of CC adverse events that are reported for orlistat, phenter-
mine, sibutramine, and topiramate. Safety signals are detected for PRR values 2.
The values are compared within antiobesity class and to all drugs in AERS.
RESULTS: A total of 41,930 adverse event reports for antiobesity agents were sub-
mitted to the AERS during the study period. About 4% and 1% of the reports were for
cardiovascular and congenital problems, respectively. Compared to all drugs in
AERS, antiobesity agents didn’t show higher than expected reporting of cardiovas-
cular events (PRR 0.71, 95%CI 0.68-0.74). However, they showed significant safety
signals regarding congenital anomalies (PRR 7.45, 95%CI 6.82-8.0), which were
mostly attributed by topiramate. Compared to other antiobesity agents, sibut-
ramine was associated with higher cardiovascular reporting rates (PRR 4.42, 95%CI
4.0-4.85), e.g. cardiac arrhythmias, pulmonary hypertension, hypertension, coro-
nary artery disease, and stroke. Phentermine was associated with valvular heart
disease (VHD), pulmonary hypertension, and stroke. Topiramate was associated
with congenital anomalies and VHD. CONCLUSIONS: Antiobesity agents should be
prescribed with caution to patients with cardiovascular risk factors. Regulatory
authorities should define cardiovascular safety surveillance requirements for an-
tiobesity agents at postmarketing stages of product’s lifecycle. An alternative to
topiramate should be prescribed to females of childbearing age. Epidemiological
studies are warranted to test the generated hypotheses.
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OBJECTIVES: COLLECT scale was developed to assess the level of comorbidity with
an impact on treatment decision for patients with Chronic Lymphocytic Leukae-
mia (CLL) in 5 steps: 1.-Literature review, 2.-Focus Group, 3.-Pilot study to evaluate
scale feasibility, 4.-Scale design, 5.-Scale validation in an observational, prospec-
tive phase IV study (evaluating safety profile of Rituximab in CLL). This communi-
cation presents the preliminary validation of the COLLECT scale.METHODS:A total
of 219 patients were included. The scale is to be fulfilled before initiating CLL
treatment and it collates and rates the presence of 11 relevant comorbidities. The
range of the score goes from 0 to 57 points. Four scoring clusters were predefined:
0-3 points (low comorbidity), 4-6 (mild comorbidity), 7-10 (moderate comorbidity)
and10 (high comorbidity). RESULTS: Data from 218 patients of 47 hospitals were
analyzed. Most frequent therapeutic scheme was Rituximab-Fludarabine-Cyclo-
phosphamide (R-FC) (41.3%), followed by Rituximab-Bendamustine (R-B) (29.6%)
and Rituximab-Chlorambucil (R-Cl) or schemes including alkylating agents (21.1%).
COLLECT median score (SD) was 4 (0-21) with a mean of 4.8 (3.1) points. 39.2% of
patients scored between 4-6 and 33% between 0-3. Statistically significant differ-
ences were observed in COLLECT score according to age (p0.01) and EGOG
(p0.01): the greater the age and ECOG, the greater the score. The election of in-
munochemotherapy treatment differed depending on the score cluster (p0.002):
50.6% and 32,9% of patients treated with R-FC had low and mild comorbidity level
respectively. 40,0% of patients receiving R-B had medium and 26.5% high comor-
bidity level. 50% of patients treated with R-Cl scored between 4-6 and the 23.5%
between 7-10. CONCLUSIONS: COLLECT scale allows defining 4 levels of comor-
bidities, with a very good correlation to age and ECOG status. Although the aim of
the scale is not to drive treatment decision, the study shows a trend to associate
comorbidity score with intensity of treatment.
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OBJECTIVES: Review the development and properties of systemic lupus erythem-
atosus (SLE) disease activity indices (DAIs) used in clinical trials, observational
studies, and case studies. METHODS: A structured search was conducted to iden-
tify published articles in 2005-2011 through key literature databases (EMBASE and
MEDLINE/PUBMED). Conference abstracts from targeted rheumatology, outcomes
research and quality-of-life scientific meetings in 2009-2011 were included. SLE
therapy clinical trials within the past five years were identified through the Clini-
calTrials.gov database. RESULTS: The search resulted in more than 15 different
DAIs, with the most frequently used being the British Isles Lupus Assessment
Group Scale (BILAG), European Consensus Lupus Activity Measure (ECLAM), Sys-
temic Lupus Activity Measure (SLAM), SLAM-revised (SLAM-R), Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI), SLEDAI-2K, Safety of Estrogen in
Lupus Erythematosus National-SLEDAI (SELENA-SLEDAI), and SLEDAI-2K-50 (SRI-
50). The number of items (24-97), time to complete (5-20 mins; 20 mins for some
tools in case of less physician training/familiarity), scoring (no global score or
0-105), organ/systems assessed (8-24), and subscales observed in these measures
varied widely. These eight DAIs all demonstrated substantial inter-rater reliability
(ICC.61-1.0) and had moderate to strong correlations with each other (r0.43-
0.97). Measures in all but BILAG were weighted. All of these tools require periodic
laboratory assessments such as hemoglobin, white cell count, complement levels,
or increased DNA binding. Ability to discriminate between-patient and between-
visit differences varied across the tools. CONCLUSIONS: BILAG and SELENA-SLE-
DAI or instruments derived from these tools are used widely in SLE clinical re-
search. However, given the complexity, clinician time required for accurate
completion, and need for lab assessments to complete these tools, further inves-
tigation is needed to assess their feasibility for use outside of the research arena in
routine clinical practice for optimal SLE management.
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OBJECTIVES: Lenalidomide (LEN) and bortezomib (BORT) are both effective for the
treatment of relapsed/refractory MM. The former is administered 25 mg/day orally
on days 1-21 of repeated 28-day cycles. The latter as a 1.3 mg/m2 intravenous dose
on days 1, 4, 8 and 11 for eight, three week cycles. Currently, there are no data from
head to head randomized trials comparing LEN and BORT. In the absence of such
data, an indirect comparison between LEN and BORT was performed in the re-
lapsed/refractory MM setting. Such an analysis was feasible because comparable
controls were used in the pivotal randomized trials and patients had similar base-
line characteristics. METHODS: Three pivotal randomized trials with LEN (n2)
and BORT (n1) in the relapsed/refractory setting were identified. Patients within
each trial had similar disease characteristics. Data in terms of response rate (RR),
time to progression (TTP) and overall survival (OS) were extracted from the pivotal
trials. An indirect statistical comparison between LEN and BORT was then per-
formed on these endpoints using the method of Bucher et al. (1997), which partly
maintains the benefits of randomization on the magnitude of benefit. RESULTS:
The analysis identified significant differences in efficacy between these drugs. Pa-
tients treated with LEN were significantly more likely to achieve a disease response
(OR1.92; 95%CI: 1.15 - 3.20) and to have a prolongation in TTP (HR  0.64; 95%CI:
0.44 - 0.91). The analysis also identified a trend for an OS benefit in patients receiv-
ing treatment with LEN over BORT (HR  0.71; 95%CI: 0.46 - 1.11). CONCLUSIONS:
A508 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
Keeping in mind the caveats associated with cross trial comparisons, the analysis
suggested increased effectiveness of LEN over BORT in MM patients with refracto-
ry/relapsed disease. These findings, along with its oral route of administration and
established safety profile suggest that LEN should be the preferred agent for refrac-
tory/relapsed MM.
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LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
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OBJECTIVES: Health care decision makers require estimates of the incremental
health benefit of any new technology relative to existing treatments. For treat-
ments targeting small patient subgroups, randomised controlled trial (RCT) data is
often unavailable requiring alternative methods to estimate comparative efficacy.
We illustrate two approaches, using the example of brentuximab vedotin.
METHODS: Brentuximab vedotin has been studied in HL patients relapsed follow-
ing ASCT (SG035-0003; Younes et al, JCO 2012). We compare 2-year survival data
from the 0003 study to: (1) A systematic review in ASCT failures – carried out
according to standard methods; no restrictions on study design/treatment. Per-
centages of patients alive at six-monthly intervals for up to five years were ex-
tracted. Comparative graphs were produced, with proportions of patients alive in
each study versus time; each point sized to reflect number of patients/study (2) A
large observational study, adjusted to reflect prognosis in 0003 – Martinez 2010,
reported OS according to whether patients had 0, 1 or 2 risk factors. Results were
reported for chemotherapy/radiotherapy and allogeneic SCT. Survival curves
for these comparators were re-weighted to reflect the proportion of patients with 0,
1 or 2 risk factors in the 0003 trial. RESULTS: Thirty-one studies reported retriev-
able OS for radiotherapy, chemotherapy, palliative care, or allogeneic SCT or ASCT.
OS for brentuximab vedotin was higher than or very similar to all but five small
(n13–38) studies. The adjusted Martinez 2010 comparison estimated 2 year OS of
48% and 65% for chemotherapy/radiotherapy and ASCT. OS for brentuximab
vedotin at 2 years is 65% comparing favourably to Martinez 2010. CONCLUSIONS:
Both methods suggested a favourable OS profile for brentuximab vedotin when
compared to other reported data sets. If available, access to individual patient data
from the Martinez 2010 study would allow use of more advanced methods to adjust
for potential confounders.
SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
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ECONOMIC EFFICIENCY OF FERRIC CARBOXYMALTOSE TO TREAT OR PREVENT
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OBJECTIVES: Among the approved intravenous iron formulations, ferric carboxy-
maltose (Ferinject®) is the most efficacious in the treatment or prevention of iron
deficiency anemia, it’s less burdensome to administer (easier and shorter time
administration) and it reduces the need for expensive resource utilization like
erythropoietin and blood transfusions. The objective was to develop a tool to assess
the relative cost-efficiency of different intravenous iron formulations in the per-
spective of the Portuguese hospitals. METHODS: A fully parameterizable Mi-
crosoft® Excel based tool was developed to compare the economic efficiency of
intravenous iron formulations available to the Portuguese hospitals: ferric car-
boxymaltose (Ferinject®); ferric hydroxide saccharose (generic and Venofer®); fer-
ric hydroxide dextran (Cosmofer®). Economic efficiency was calculate as the bal-
ance between hospitals incurred costs relative to the number of patients to be
treated, the dose and number of administrations of intravenous iron, and the need
for erythropoietin and blood transfusions. The tool default values are from a liter-
ature review used to populate the model. The tool allows studying the cost and
benefits of treating/preventing chronic kidney disease, inflammatory bowel dis-
ease, chemotherapy, and orthopedic surgery related anemia. RESULTS: Ferric hy-
droxide saccharose (generic) is to the most used and lower price intravenous iron in
Portugal. Relative to generic ferric hydroxide saccharose (FHS), ferric carboxymalt-
ose (FC) is estimated to lower mean per patient annual costs in all four anemic
conditions in major hospitals: 3,087.60€ (FC) vs. 3,482.20€ (FHS) for chronic kidney
disease; 2,195.75€ (FC) vs. 2,427.4€ (FHS) for inflammatory bowel disease; 3,626.17€
(FC) vs. 3,793.13€ (FHS) for chemotherapy; and 3,485.74€ (FC) vs. 3,849.47€ (FHS) for
orthopedic surgery. These results were consistent irrespective of the type of
hospital. CONCLUSIONS: This is a valuable tool to inform hospital decison makers
about the economic value of ferric carboxymaltose as compared to other intrave-
nous iron formulations.
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SOCIETAL BURDEN ASSOCIATED WITH NEUROPATHIC PAIN IN EUROPE
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OBJECTIVES: Neuropathic Pain (NeP) is a common disorder that can be chronic,
severe and disabling, While the burden regarding quality of life and health care
costs is understood, societal costs are less researched. This analysis addresses the
implications in terms of work productivity loss and caregiver needs. METHODS:
Data were drawn from the 2012 Adelphi NeP Disease Specific Programme, a, cross-
sectional survey of 121 primary care physicians and 292 specialists and their pa-
tients run in five European countries (France, Germany, Italy, Spain and the UK).
Physicians provided data relating to diagnosis, treatment patterns and caregiver
requirements, patients were invited to fill a self-completion questionnaire includ-
ing the Work Productivity and Activity Impairment (WPAI) questionnaire.
RESULTS:A total of 3956 patients were included, of whom 2639 were of working age
and 1341 in either full or part time employment. 23% of those employed were
currently on sick leave, with mean duration of absence being 10 weeks. A total of
751 patients completed the WPAI; of whom 30% reported that NeP had stopped
them from working (limited periods or permanently). These patients reported ab-
senteeism from work 23% of the time. Whilst at work, on a scale of 0 (no effect) to
10 (complete prevention from work) patients reported a mean score of 4.4, implying
significantly reduced on-the-job effectiveness. Regarding regular daily activities
(housework, shopping etc.) on a similar scale from 0 to 10 patients again reported a
value of 4.4; 19% of patients had a caregiver responsible for their daily activities.
The most common caregiver was partner/spouse (66%) while only 15% received
care from a professional caregiver. The mean amount of care provided was 27
hours per week across Europe, ranging from 10 hours (France) to 48 hours (Italy).
CONCLUSIONS: This abstract implies evidence suggesting a major societal burden
within humanistic and economic societal burden associated with NeP in Europe.
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OBJECTIVES: NNT can be a useful approach to compare treatments in the absence
of direct comparative clinical trials. Imatinib, nilotinib and dasatinib are approved
as first-line treatments for patients newly diagnosed with Philadelphia chromo-
some positive chronic myeloid leukemia in the chronic phase (CP-CML). The objec-
tive of this analysis is to compare these treatments with regards to: (1) the NNT to
achieve one MMR by 12 months (2) the cost of achieving one MMR and the annual
cost treatment including of adverse events (AEs) from the perspective of the Greek
National Health System (NHS). METHODS: MMR and AE rates were taken from the
CML-CP frontline trials –DASISION (dasatinib 100mg QD vs. imatinib 400mg QD)
and ENESTnd (nilotinib 300mg BID vs imatinib 400mg QD). The NNT was calculated
as the inverse of the MMR rate by 12 months (1/MMR). AE management costs were
estimated from patient records at Evangelismos Hospital and multiplied by the
incidence reported in the trials. RESULTS: The nilotinib NNT was 51% lower than
the imatinib NNT in ENESTnd (1.8 vs. 3.7) and the dasatinib NNT was 39% lower that
the imatinib NNT in DASISION (2.2 vs. 3.6). Annual cost of nilotinib including cost of
AEs is estimated at €34.349, dasatinib €35.504 and of imatinib €25.040. The cost of
achieving 1 MMR is €62.453 for nilotinib, €78.389 for dasatinib and €92.741 for ima-
tinib. Therefore, the cost of achieving 1 MMR with nilotinib is lower by 20,33% vs.
dasatinib and 33% vs. imatinib. CONCLUSIONS: The NNT findings and the differ-
ential cost of managing AEs in each treatment from this evaluation suggests that
nilotinib provides better clinical outcomes and would result in lower costs for
hematologic AE management from the perspective of the Greek NHS.
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OBJECTIVES:To evaluate the health care and productivity costs in chronic low back
pain (CLBP) patients with a probable neuropathic pain (NeP) component before and
after the initiation of pregabalin, gabapentin or a TCA (tricycle antidepressant).
METHODS: Patients with primary diagnosis of CLBP (ICD-10: M43, M45-48, M50-51,
M53-54) and at least two prescription claims for either pregabalin, gabapentin or a
TCA were identified using data from the National Patient Registry, the Medicinal
Registry, and other registries (2004-2010). Patients identified with generalized anx-
iety disorders or seizures were excluded. The index date was considered the first
prescription for pregabalin, gabapentin or a TCA. Descriptive assessments of
health care and productivity costs were conducted 12 months pre and 12 months
post the index date using the full dataset. To control for selection bias, a propensity
score matched cohort controlling for age, gender, socioeconomic status, education,
depression, and health care resource use was also conducted. Statistical tests per-
formed were Wilcoxon (0.05). RESULTS: A total of 6,028 of 7,282 CLBP patients
with NeP met the inclusion criteria (treatment courses included: 3,507 TCA; 2,735
gabapentin; 1,293 pregabalin). Twelve months health care costs increased signifi-
cantly in all 3 groups (€377 - €1,113) (P0.001). Matched sub-analyses covering 1,217
patients in each group showed similar significant health care cost increases; how-
ever, the pregabalin group was the only group to result in a significant reduction in
hospitalization costs (P0.03). Across all three groups number of job losses was
reduced, whereas long-term sickness increased; however, insignificantly so in the
pregabalin group. CONCLUSIONS: This study showed increasing healthc are costs
12 months after the initiation of NeP drug treatment in CBLP patients with NeP. In
matched analyses the increased health care costs in the pregabalin group were
partly offset by significant savings in hospitalization costs. Production lost in-
creased in all three groups; however, only significant in the TCA and gabapentin
groups.
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AN INDIRECT COMPARISON OF ICATIBANT AND FOUR OTHER THERAPIES FOR
THE SYMPTOMATIC TREATMENT OF ACUTE ATTACKS OF HEREDITARY
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